All AbMole products are for research use only, cannot be used for human consumption.
Pirtobrutinib (LOXO-305, LY 3527727, RXC-005) is a first-in-class, highly selective, non-covalent BTK inhibitor that inhibits multiple BTK C481 substitution mutations. Pirtobrutinib is more than 300-fold selective for BTK compared to 370 other kinases.Pirtobrutinib inhibits both wild-type BTK and BTK C481S-mediated kinase activity with nanomolar potency.Pirtobrutinib inhibits autophosphorylation of WT BTK (Y223) with an IC50 of 3.68 nM. Pirtobrutinib inhibited the autophosphorylation of WT BTK (Y223) with an IC50 of 3.68 nM. Pirtobrutinib inhibited the autophosphorylation of BTK C481S Y223, C481T Y223, and C481R Y223, with IC50s of 8.45, 7.23, and 11.73 nM, respectively.
| Molecular Weight | 479.43 |
| Formula | C22H21F4N5O3 |
| CAS Number | 2101700-15-4 |
| Solubility (25°C) | DMSO 60 mg/mL |
| Storage | 2-8°C, sealed |
[2] Diana Romero. Nat Rev Clin Oncol. Initial pirtobrutinib data show promise
| Related BTK Products |
|---|
| BIIB129
BIIB129 is a covalent, selective inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of BTK by covalently binding to Cys481 in BTK, thereby affecting the function of B cells and myeloid cells. |
| UBX-382
UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling. |
| GDC-0834
GDC-0834 is a potent and selective BTK inhibitor. |
| DD-03-171
DD-03-171 is a BTK, IKFZ1 and IKFZ3 degrader, the BTK IC50 a value of 5.1 nM. |
| N-piperidine Ibrutinib hydrochloride
N-piperidine Ibrutinib hydrochloride is a reversible Ibrutinib derivative. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
